
Feature|Articles|September 18, 2026
Understanding the Latest with MFN Pricing and What It Means to Pharma
Author(s)Alan Crowther
EVERSANA's Alan Crowther on why MFN's three programs, compounding interactions with IRA and 340B, and leverage gaps make it pharma's most consequential pricing challenge.
Advertisement
Advertisement
On August 31, the Trump Administration expanded its Most-Favored-Nation (MFN) drug pricing initiative by securing agreements with nine additional pharmaceutical companies. Pharmaceutical Executive connected with Alan Crowther, who leads EVERSANA’s global pricing and access business and the company’s leading pricing platform, Navlin, to discuss what the updates to MFN could mean to the industry.
Related to this article

FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors.

FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.

FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Advertisement
Advertisement

